Ildong Pharmaceutical buys ~$27M stake in cancer-drug developer Idience
What's the deal? Ildong PharmaceuticalDealroom has a profile for this one. Try Dealroom → is acquiring 7,097,016 redeemable convertible preferred shares (RCPS) in Idience, an anticancer drug developer within the Ildong GroupDealroom has a profile for this one. Try Dealroom →, for 36.75 billion Korean won (about $27 million) in cash. The board approved the purchase on September 30, lifting Ildong's stake to 13.95%.
The fine print: RCPS are preferred shares that carry the right to redeem the investment or convert to common stock under set conditions. The deal covers US$26.6M of Series A investments and roughly US$4.19M of Series B, and equals 15.35% of Ildong Pharmaceutical's equity as of the end of last year.
What's the endgame? Ildong said the move aims to strengthen ties across its new drug pipelines and sharpen its competitiveness in drug development. Idience is developing Venadafip, a PARP1 selective inhibitor.
Why now? The transaction transfers stock purchase rights previously held by external financial investors against Ildong HoldingsDealroom has a profile for this one. Try Dealroom → to Ildong Pharmaceutical. Ildong Holdings amended its Series B disclosure the same day, naming Ildong Pharmaceutical as the investor in place of the Kiwoom-Yuanta 2019 Scale-up FundDealroom has a profile for this one. Try Dealroom → and others.
What could go wrong? The special agreement letting investors exercise purchase rights if Idience missed follow-up funding targets has been deleted. But general purchase rights remain in force for contract breaches, misuse of funds, critical asset leakage, business suspension, or delays in an initial public offering.
The signal: The deal deepens corporate backing for Venadafip, which drew about US$21M from Dong-A STDealroom has a profile for this one. Try Dealroom → in 2024 — a bet that made it Idience's second-largest shareholder and a partner in developing a Venadafip combination therapy. Consolidating investor rights inside the group signals Ildong is building a tighter, more controlled path toward commercialising its cancer pipeline.
Read more: chosun.com
Image credit: Generated with Gemini
